e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Idiopathic pulmonary fibrosis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment with nintedanib in patients with pleuroparenchymal fibroelastosis
M. Nasser (Bron, France)
Source:
International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Session:
Idiopathic pulmonary fibrosis: from the bench to the bedside
Session type:
Poster Discussion
Number:
4876
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Nasser (Bron, France). Treatment with nintedanib in patients with pleuroparenchymal fibroelastosis. 4876
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
Lung function assessment in octogenarians with lung cancer diagnosis
Home-based telerehabilitation program using real-time monitoring and interactive exercise for patient with lung cancer: A feasibility study
Related content which might interest you:
Clinical courses of asymptomatic patients with mild idiopathic pleuroparenchymal fibroelastosis
Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children
Year: 2018
Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia
Source: ERJ Open Res, 7 (1) 00196-2020; 10.1183/23120541.00196-2020
Year: 2021
The health status in idiopathic pleuroparenchymal fibroelastosis
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Clinical and pathological features of idiopathic and secondary pleuroparenchymal fibroelastosis in patients undergoing lung transplantation
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents
Source: Eur Respir J 2014; 44: 523-527
Year: 2014
Predicting factors for mortality in patients with pleuroparenchymal fibroelastosis
Source: International Congress 2017 – Rare diseases
Year: 2017
Clinical investigation of idiopathic pleuroparenchymal fibroelastosis cases diagnosed by radiologic findings and fibroelastosis obtained by TBLB
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014
Pleuroparenchymal fibroelastosis as a manifestation of chronic lung rejection?
Source: Eur Respir J 2013; 41: 243-245
Year: 2013
Air-leak syndrome caused by pleuroparenchymal fibroelastosis after bone marrow transplantation
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes
Source: Eur Respir J 2012; 40: 377-385
Year: 2012
Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Pleuroparenchymal fibroelastosis - clinical analysis of 22 cases
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Pleuroparenchymal fibroelastosis (PPFE) – Resembling features in patients with malignancies
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial
Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias
Year: 2018
Registry of idiopathic pulmonary fibrosis patients
Source: International Congress 2016 – Russia Session
Year: 2016
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept